Shopping Cart
- Remove All
Your shopping cart is currently empty
(76)
Angiogenesis
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
Filter
Angiogenesis Tyrosine Kinase/AdaptorsACK
(5)
ALK
(76)
BTK
(81)
Bcr-Abl
(78)
CSF-1R
(18)
DYRK
(26)
Discoidin Domain Receptor (DDR)
(11)
EGFR
(298)
Ephrin Receptor
(18)
FAK
(46)
FGFR
(113)
FLT
(112)
HER
(66)
Hck
(4)
IGF-1R
(56)
PDGFR
(107)
PKA
(71)
PYK2
(7)
ROS Kinase
(20)
Src
(119)
Syk
(38)
TAM Receptor
(45)
Tie-2
(9)
Trk receptor
(54)
Tyrosine Kinases
(58)
VEGFR
(226)
c-Fms
(42)
c-Kit
(84)
c-Met/HGFR
(97)
c-RET
(42)
Src
Src kinase family is a family of non-receptor tyrosine kinases that includes nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. Frk has homologs in invertebrates such as flies and worms, and Src homologs exist in organisms as diverse as unicellular choanoflagellates, but the SrcA and SrcB subfamilies are specific to vertebrates. Src family kinases contain six conserved domains: a N-terminal myristoylated segment, a SH2 domain, a SH3 domain, a linker region, a tyrosine kinase domain, and C-terminal tail.
- eCF506T84991914078-41-3eCF506 is a potent and selective inhibitor of SRC (IC50 < 0.5 nM)
- $40
SizeQTY
- StaurosporineT668062996-74-1Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6 15 2 3 3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.
- $56
SizeQTY
Cited - IbrutinibT1835936563-96-1Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
SizeQTY Cited - NintedanibT1777656247-17-5Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
- $38
SizeQTY Cited - TAK-901T2709934541-31-8TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
- $66
SizeQTY Cited - Cyt-PTPε Inhibitor-1T10927428478-94-8In houseCyt-PTPε Inhibitor-1 (A Inhibitor-1) is an inhibitor of cytosolic protein tyrosine phosphatase ε. Cyt-PTPε Inhibitor-1 blocks the dephosphorylation of c-Src and exhibits anti-osteoclastic activity.
- $58
SizeQTY
- SI-2 hydrochlorideT129061992052-49-9SI-2 hydrochloride (EPH 116 hydrochloride) is a highly promising inhibitor of SRC-3 SMI: SRC-3 (PPI)(IC50 values of 3-20 nM for breast cancer cell death), with acceptable oral availability.
- $30
SizeQTY - KX2-361T9411897016-26-1In houseKX2-361 is a orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma
- $123
SizeQTY - LCB 03-0110 dihydrochlorideT326131962928-28-4In houseLCB 03-0110 Dihydrochloride is a potent inhibitor of the c-Src kinase (IC50 = 1.3 nM) and tyrosine kinases in the BTK and SYK family, as well as in the DDR2 family. It inhibits LPS-induced activation of macrophages and TGF-β1-induced activation of fibroblasts in vitro, inhibits activation of macrophages and fibroblasts, and inhibits scarring in wound healing models.
- $71
SizeQTY - CpCDPK1/TgCDPK1-IN-1T786051092788-23-2In houseCpCDPK1/TgCDPK1-IN-1 is a potent dual inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections and cryptosporidiosis.
- $350
SizeQTY - Osteogenic Growth Peptide (10-14) acetateT37603LOsteogenic Growth Peptide (10-14) acetate (Osteogenic Growth Peptide) is a Src inhibitor and an effective mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acetate is responsible for the binding to the OGP receptor and activates an intracell
- $227
SizeQTY - BGB-102T10531807640-87-5BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
- $328
SizeQTY - AP23846T68455878654-51-4In houseAP23846 is a novel and potent Src family kinase inhibitor that reduces vascular endothelial growth factor and interleukin-8 expression and abrogates downstream angiogenic processes in human solid tumor cell lines.
- $293
SizeQTY - $293
- GW297361T75163388627-21-2GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 and Pho85 were 20 nM and 400 nM, respectively.
- $247
SizeQTY - CGP77675T30855234772-64-6In houseCGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylation of purified Src. CGP77675 exhibits anticancer activity.
- $43
SizeQTY - ARN25068T613602649882-80-2In houseARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses tau hyperphosphorylation [1].
- $115
SizeQTY - A 419259 trihydrochlorideTQ01321435934-25-0In houseA 419259 trihydrochloride (RK 20449 trihydrochloride) is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).
- $48
SizeQTY - AZ12672857T9650945396-55-4In houseAZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphorylation of EphB4 in transfected CHO-K1 cells with IC50 of 9 nM.
- $64
SizeQTY - TG 100801T13157867331-82-6In houseTG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).
- $84
SizeQTY - TG 100572 HydrochlorideT13156L867331-64-4In houseTG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively).
- $399
SizeQTY - WAY-600T67301062159-35-6In houseWAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1 P-S6K(T389) and mTORC2 P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold).
- $32
SizeQTY - RepotrectinibT40711802220-02-5Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
- $45
SizeQTY Cited - PP121T24151092788-83-4PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , also inhibits DNA-PK (IC50: 60 nM).
- $51
SizeQTY Cited - TirbanibulinT6345897016-82-9Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.
- $35
SizeQTY Cited - AD80T43011384071-99-1AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
- $39
SizeQTY Cited - BosutinibT0152380843-75-4Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
- $37
SizeQTY Cited - PP1T6196172889-26-8PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck Fyn is 5 nM 6 nM, respectively.
- $34
SizeQTY Cited - BafetinibT6311859212-16-1Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl Lyn inhibitor (IC50: 5.8 19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.
- $31
SizeQTY Cited - TofacitinibT6321477600-75-2Tofacitinib (Tasocitinib) is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.
- $30
SizeQTY Cited - OSI-930T2624728033-96-3OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors.
- $47
SizeQTY Cited - Dasatinib monohydrateT1448L863127-77-9Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
- $33
SizeQTY Cited - ScutellareinT3319529-53-3Scutellarein (6-Hydroxyapigenin) reduces inflammatory responses by inhibiting Src kinase activity.
- $110
SizeQTY Cited - VemurafenibT2382918504-65-1Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
SizeQTY Cited - MLN8054T6315869363-13-3MLN8054 is a potent and selective Aurora A kinase inhibitor with an IC50 of 4 nM.
- $48
SizeQTY Cited - SaracatinibT6078379231-04-6Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
- $59
SizeQTY Cited - RebastinibT26401020172-07-9DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
- $40
SizeQTY Cited - 5α-Hydroxycostic acidTN3139132185-83-25alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.
- $162
SizeQTY Cited - DasatinibT1448302962-49-8Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitumor activity and is used in the treatment of leukemia and lymphoma.
- $37
SizeQTY Cited - PP2T6266172889-27-9PP2 (AG 1879,AGL 1879) is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
- $39
SizeQTY Cited - PelitinibT2327257933-82-7Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
- $43
SizeQTY Cited - PonatinibT2372943319-70-8Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).
- $50
SizeQTY Cited - PD173074T2642219580-11-7PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
- $36
SizeQTY Cited - 1-Naphthyl PP1 hydrochlorideT7371956025-47-11-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases v-Src
- $31
SizeQTY - GluR6 antagonist-1T9723323176-64-3GluR6 antagonist-1 inhibits the pY binding site of tyrosine kinase p56lck SH2 domain.
- $38
SizeQTY - NCGC00262650T8995344359-25-7NCGC00262650 is an inhibitor of AMA1-RON2 interaction and c-Src tyrosine kinase activity.
- $34
SizeQTY - 7-Hydroxy-4H-chromen-4-oneT734559887-89-77-Hydroxy-4H-chromen-4-one (7-hydroxy-4-benzopyrone) is a Src kinase inhibitor (IC50 of <300 μM).
- $30
SizeQTY - AD57T22552L1093380-42-7AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
- $47
SizeQTY - Masitinib mesylateT85441048007-93-7Masitinib mesylate (AB-1010 mesylate) is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectively).
- $30
SizeQTY - RK-24466T16760213743-31-8RK-24466 (KIN 001-51) is a selective and potent inhibitor of Lck, inhibits Lck (64-509) and LckCD isoforms with IC50s of less than 1 and 2 nM, respectively.
- $60
SizeQTY
Go to page 1
Page of 3
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.